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Involvement of a volatile metabolite during phosphoramide mustard-
induced ovotoxicity
Abstract
The finite ovarian follicle reserve can be negatively impacted by chemical exposures including the anti-
neoplastic agent, cyclophosphamide (CPA). CPA requires bioactivation to phosphoramide mustard (PM) to
elicit its therapeutic effects however; in addition to being the tumor-targeting metabolite, PM is also ovotoxic.
In addition, PM can break down to a cytotoxic, volatile metabolite, chloroethylaziridine (CEZ). The aim of
this study was initially to characterize PMinduced ovotoxicity in growing follicles. Using PND4 Fisher 344
rats, ovaries were cultured for 4 days before being exposed once to PM (10 or 30 μM). Following eight
additional days in culture, relative to control (1% DMSO), PM had no impact on primordial, small primary or
large primary follicle number, but both PM concentrations induced secondary follicle depletion (P < 0.05).
Interestingly, a reduction in follicle number in the control-treated ovaries was observed. Thus, the involvement
of a volatile, cytotoxic PM metabolite (VC) in PM-induced ovotoxicity was explored in cultured rat ovaries,
with control ovaries physically separated from PM-treated ovaries during culture. Direct PM (60 μM)
exposure destroyed all stage follicles after 4 days (P < 0.05). VC from nearby wells depleted primordial
follicles after 4 days (P < 0.05), temporarily reduced secondary follicle number after 2 days, and did not
impact other stage follicles at any other time point. VC was determined to spontaneously liberate from PM,
which could contribute to degradation of PM during storage. Taken together, this study demonstrates that PM
and VC are ovotoxicants, with different follicular targets, and that the VC may be a major player during PM-
induced ovotoxicity observed in cancer survivors.
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Abstract
The finite ovarian follicle reserve can be negatively impacted by chemical exposures including the
anti-neoplastic agent, cyclophosphamide (CPA). CPA requires bioactivation to phosphoramide
mustard (PM) to elicit its therapeutic effects however; in addition to being the tumor-targeting
metabolite, PM is also ovotoxic. In addition, PM can break down to a cytotoxic, volatile
metabolite, chloroethylaziridine (CEZ). The aim of this study was initially to characterize PM-
induced ovotoxicity in growing follicles. Using PND4 Fisher 344 rats, ovaries were cultured for 4
days before being exposed once to PM (10 or 30 μM). Following eight additional days in culture,
relative to control (1% DMSO), PM had no impact on primordial, small primary or large primary
follicle number, but both PM concentrations induced secondary follicle depletion (P < 0.05).
Interestingly, a reduction in follicle number in the control-treated ovaries was observed. Thus, the
involvement of a volatile, cytotoxic PM metabolite (VC) in PM-induced ovotoxicity was explored
in cultured rat ovaries, with control ovaries physically separated from PM-treated ovaries during
culture. Direct PM (60 μM) exposure destroyed all stage follicles after 4 days (P < 0.05). VC from
nearby wells depleted primordial follicles after 4 days (P < 0.05), temporarily reduced secondary
follicle number after 2 days, and did not impact other stage follicles at any other time point. VC
was determined to spontaneously liberate from PM, which could contribute to degradation of PM
during storage. Taken together, this study demonstrates that PM and VC are ovotoxicants, with
different follicular targets, and that the VC may be a major player during PM-induced ovotoxicity
observed in cancer survivors.
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Introduction
Cyclophosphamide (CPA) is used, alone or in combination, to treat an array of cancers and
autoimmune disorders, and elicits numerous undesirable health side effects including
alopecia, nausea, immunosuppression and infertility (Fraiser et al., 1991). As a prodrug,
CPA requires bioactivation to the metabolite phosphoramide mustard (PM) in order to
induce anti-neoplastic effects (Shulman-Roskes et al., 1998). Bioactivation of CPA to PM
occurs through a cascade of reactions (Fig. 1) that are initiated primarily by the hepatic
cytochrome P450 enzymes (CYPs) isoforms 2B and 3A (Philip et al., 1999). These CYPs
hydroxylate CPA to form 4-hydroxycyclophosphamide, which is non-enzymatically
transformed to the open-ring metabolite, aldophosphamide. Aldophosphamide fragments,
producing the compounds acrolein and PM (Ludeman, 1999).
Interestingly, PM can further transform into a volatile, cytotoxic compound
chloroethylaziridine (CEZ; Rauen and Norpoth, 1968; Lu and Chan, 1996). CEZ was first
identified as a volatile metabolite of CPA in 1968, when approximately 2% of the CPA
administered was shown to be exhaled as CEZ from the lungs of exposed rats (Rauen and
Norpoth, 1968). CEZ was also found to be responsible for the airborne cytotoxicity,
observed in untreated cells cultured adjacent to cells exposed to CEZ-producing compounds,
termed the “neighboring well effect” (Flowers et al., 2000). Although the generation of CEZ
has been demonstrated both in vivo and in vitro, determining the relative contribution of
CEZ to CPA-induced cytotoxicity has proven difficult due to the compound’s volatility and
the instability of its precursor, PM. CEZ plasma concentrations were shown to peak 5
minutes after intravenous PM administration in rats (Lu and Chan, 2006). An additional
study demonstrated that following complete degradation of PM in solution, 85% of the
solution’s cytotoxicity remained due to the generation and continued presence of CEZ (Chan
et al., 1994). Taken together, these studies support that CEZ is a major degradation product
of CPA/PM and suggests that CEZ may play a key role in the toxicity of CPA.
CPA-induced side effects are of growing concern as cancer survival rates continue to
improve. In particular, increased cancer survival rates have resulted in a greater number of
female cancer survivors affected by CPA-induced infertility (Linet et al., 1999; Sklar et al.,
2006; Pulte et al., 2008). Female fertility is dependent on the quality of oocytes, which are
maintained within the ovary as follicular structures, consisting of a meiotically-arrested
oocyte surrounded by granulosa cells. The ovarian follicular reserve is established at birth
and progressively declines until menopause or ovarian failure, the point at which no follicles
remain (Hirshfield, 1991). Chemical exposures, including CPA, accelerate follicular death
and subsequent decline of the follicular reserve leading to premature ovarian failure (POF),
thus causing permanent infertility (Plowchalk and Mattison, 1991). Aside from sustaining
fertility, the survival of these follicles is important to overall female health; POF increases
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the risk of various health conditions including osteoporosis and heart disease (Greendale et
al., 1999).
CPA-induced infertility is attributed to the generation of PM because, in addition to being
the anti-neoplastic metabolite, PM is also recognized as the ovotoxic CPA metabolite
(Plowchalk and Mattison, 1991; Desmeules and Devine, 2006). However, CEZ has also
been suggested to be ovotoxic due to observed loss of primordial follicles induced by a
volatile breakdown product of PM in a neonatal rat ovarian culture model (Desmeules and
Devine, 2006). Therefore, in addition to PM, CEZ may be at least partially responsible for
both the anti-neoplastic and ovotoxic properties of CPA. The purpose of the current study
was initially to determine the impact of acute exposure to PM on large growing follicles,
which led to the characterization of the ovotoxicity of a volatile compound (VC),
presumably CEZ, liberated from PM using a neonatal rat ovary culture system. Specifically,
the temporal pattern of PM- and VC-induced follicle loss was characterized, the requirement
of ovarian tissue for VC liberation was determined and the impact of storage on PM-induced
ovotoxicity at −20°C was evaluated.
Materials and Methods
Reagents
Bovine serum albumin (BSA), ascorbic acid, transferrin, formaldehyde, dimethyl sulfoxide
(DMSO) were purchased from Sigma Aldrich Inc. (St. Louis, MO). Dulbecco’s Modified
Eagle Medium: nutrient mixture F-12 (Ham) 1x (DMEM/Ham’s F12), Albumax, penicillin
(5000U/ml) Hank’s Balanced Salt Solution (without CaCl2, Mg Cl2, or MgSO4) were
obtained from Invitrogen Co. (Grand Island, NY). Millicell-CM filter inserts and 48-well
cell culture plates were obtained from Millipore (Billerica, MA) and Corning Inc. (Corning,
NY), respectively. Phosphoramide mustard was obtained from the National Institutes of
Health National Cancer Institute (Bethesda, MA).
Animals
Fisher 344 (F344) rats were housed one per plastic cage and maintained in a controlled
environment (22 ± 2°C; 12h light/12h dark cycles). The animals were provided a standard
diet with ad libitum access to food and water and allowed to give birth. The University of
Arizona and Iowa State University Institutional Animal Care and Use Committee approved
all experimental procedures.
Ex vivo ovarian cultures
Ovaries were collected from female postnatal day (PND) 4 F344 rats and cultured as
described by Devine et al., 2002. Ovaries were removed, trimmed of oviduct and other
excess tissue, and placed onto a Millicell-CM membrane floating on 250 μl of previously
37°C equilibrated DMEM/Ham’s F12 medium containing 1 mg/ml BSA, 1 mg/ml Albumax,
50 μg/ml ascorbic acid, 5 U/ml penicillin and 27.5 μg/ml transferrin per well in a 48-well
plate. A drop of medium was placed on top of each ovary to prevent dehydration and
maintained at 37°C and 5% CO2.
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Effect of single exposure PM on growing follicles—Ovaries (n = 3/treatment) were
cultured for four days to allow large primary and secondary follicles to develop in culture
before being treated once with vehicle control media (1% DMSO), PM (10 μM or 30 μM)
and maintained in culture for an additional eight days. These concentrations were based on
those previously described (Petrillo et al., 2011).
Ovotoxicity time course—Ovaries (n = 3–4/treatment) were treated on alternate days
with vehicle control DMSO (1%), PM (60 μM) or VC for 2, 4 or 6 days. These PM
concentrations were chosen to achieve a phenotypic endpoint of approximately 50%
primordial follicle loss and to achieve sufficient VC liberation for ovotoxicity evaluation.
All PM-treated ovaries were maintained in a separate incubator from the control-treated
ovaries (CT). VC-exposed ovaries were cultured in control media in the same incubator as
the PM treated ovaries, but on separate plates from the PM samples, thus the ovaries were
exposed to the volatile metabolite liberated from PM-treated wells.
Evaluation of ovarian-required VC generation—Ovaries (n = 4) were cultured for six
days in control media adjacent to wells that were treated on alternate days with PM (60 μM)
but did not contain an ovary (Fig. 2).
Evaluation of PM degradation during storage—Cultured ovaries (n = 4) were treated
on alternate days with freshly suspended PM (“New”) or with previously suspended PM,
which had been stored for two years in DMSO at −20°C (“Old”). Ovaries were cultured for
six days in separate incubators to reduce VC-induced ovotoxicity as a confounding factor.
Histological evaluation of follicle numbers
Following treatment, ovaries were placed in 4% paraformaldehyde fixative for 2 hours,
washed and stored in 70% ethanol, paraffin embedded, and serially sectioned (5 μM) at the
histology laboratory in the Department of Veterinary Pathology (Iowa State University).
Every 6th section was mounted and stained with hematoxylin and eosin. Healthy oocyte-
containing follicles were identified and counted in every 6th section. Unhealthy follicles
were identified from healthy follicles by the appearance of pyknotic bodies and intense
eosinophilic staining of oocytes. Healthy follicles were classified and enumerated according
to Flaws et al., 1994. Slides were blinded to prevent counting bias.
Statistical analysis
Comparisons were made between treatments for follicle count experiments using Analysis
of Variance (ANOVA) and t-tests comparing treatment with control data at each individual
time-point. All statistical analysis was performed using Prism 5.04 software (GraphPad
Software). Statistical significance was defined as P < 0.05.
Results
Effect of single PM exposure on growing ovarian follicles
To gain an understanding of the impact of PM on growing ovarian follicles, PND4 rat
ovaries were cultured for four days in control media in order for larger follicles to develop
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prior to exposure. Ovaries were treated with vehicle control, 10 μM PM or 30 μM PM and
maintained in culture for eight additional days. Ovaries were histologically evaluated,
follicles classified and enumerated. Neither concentration of PM induced loss of primordial
(Fig. 3A), small primary (Fig. 3B) or large primary (Fig. 3C) follicles. However, PM
exposure caused secondary follicle loss (P < 0.05) at both concentrations (Fig. 3D). This
experiment demonstrates that even single acute exposure of PM can deplete ovarian
follicles.
Temporal pattern of PM- and VC-induced follicle loss
To determine the temporal pattern of PM-induced ovotoxicity, as well as investigate the
liberation of VC and evaluate the ovotoxicity of VC relative to PM, PND4 rat ovaries were
cultured in medium containing vehicle control (Fig. 4A), PM (60 μM; Fig. 4B) or VC (Fig
4C) for 2, 4, or 6 days. The plate containing control ovaries was removed to a separate
incubator. The VC-exposed ovary was placed onto a membrane floating on control medium,
maintained on a separate culture plate but in the same incubator as the culture plate
containing an ovary floating on PM-treated media. Media was replaced on alternate days
and culture was maintained for 2, 4 or 6 days. Following culture, ovaries were sectioned,
stained with hematoxylin and eosin and healthy follicles were classified and counted.
After two days of exposure, there was no impact of PM on follicle number (Fig. 4D–G).
However, following four days of culture, PM induced primordial (Fig. 4D), small primary
(Fig. 4E) and large primary follicle (Fig. 4F) loss (P < 0.05). After six days of PM exposure,
primordial (Fig. 4D), small primary (Fig. 4E) and large primary (Fig. 4F) follicles were
depleted (P < 0.05).
Primordial (Fig. 4D) follicle numbers were reduced by VC exposure (P < 0.05) after four
days, however with the exception of loss (P < 0.05) of secondary follicles after two days of
exposure (Fig. 4G), VC did not impact the number of small primary, large primary, or
secondary follicles, indicating that while PM can deplete all stage follicles, that the primary
target of VC is likely the primordial follicle.
Compared to control, ovaries exposed to either PM or VC had a distinct empty ring between
the oocyte and the granulosa cells, which occurred most obviously in the larger follicles, but
also occurred in the small follicle types. It appears the oocyte has shrunk away from the
granulosa cells resulting in an observable “gap” induced by PM (Fig. 4B) and VC (Fig. 4C)
exposure.
Biotransformation requirement for CEZ liberation from PM
To determine whether VC generation requires ovarian biotransformation, PND4 rat ovaries
were cultured for six days in control media in Incubator A (Fig. 2). In Incubator B ovaries
were plated adjacent to wells lacking an ovary. The wells that did not contain an ovary were
treated on alternate days with PM (60 μM) to allow for potential spontaneous, ovarian-
independent generation of VC. The neighboring, untreated ovaries were evaluated for
ovotoxicity via follicle classification and counting. Relative to control, primordial (Fig. 5A)
and small primary follicles (Fig. 5B) were depleted (P < 0.05) as a result of ovarian-
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independent generation of VC. Also, there were very few large primary and complete
absence of secondary follicles in the VC exposed ovaries, though variation in the CT-treated
ovaries negated statistical significance. Thus, there is no requirement for ovarian enzyme-
mediated biotransformation of PM to VC.
Impact of storage condition on PM degradation
We observed an apparent loss of potency in terms of ovotoxicity of PM aliquots stored for
approximately two years in DMSO. To confirm this observation and evaluate PM
degradation under −20 °C storage conditions, PND4 ovaries were cultured with either two-
year old PM (“Old”; 60 μM) or newly dissolved PM (“New”; 60 μM) on alternate days for
six days. Following hematoxylin and eosin staining, follicles were classified and counted.
Equal primordial follicle numbers (Fig. 6A) were observed between new and old PM
aliquots. However, new PM caused loss (P < 0.05) of small primary (Fig. 6B) and large
primary (Fig. 6C) follicles, compared to old PM aliquots. Additionally, there were no
secondary follicles present in the ovaries exposed to new PM (Fig. 6D). These data indicate
the importance of proper storage conditions when evaluating cytotoxicity of PM.
Discussion
The primordial follicle pool encompasses the ovarian follicle reserve and the maintenance of
these irreplaceable structures is essential for female fertility. If activated to grow and mature
out of the primordial follicle pool, follicles will either progress toward ovulation or die by
atresia. The balance of these processes is vital to preserving fertility throughout the lifespan
of a female. Chemical exposures can disturb this balance leading to increased activation out
of the follicle reserve (Keating et al., 2009) as well as increased atresia (Hu et al., 2001a; Hu
et al., 2001b), which if continued, can ultimately result in infertility or POF. If an
ovotoxicant targets the large pre-ovulatory follicles, once the exposure ceases, the
primordial follicles can still be recruited and develop to ovulation, thus only inducing
temporary infertility (Keating and Hoyer, 2009). However, if the primordial follicles are
depleted, permanent infertility will ensue.
Our initial goal of this study was to investigate the impact of a single PM exposure on the
growing follicle pool, which revealed that a single exposure to PM depleted secondary
follicles. Interestingly, the control follicle numbers in this experiment were lower than
expected compared to our previous experiments using the same culture system (Keating et
al., 2009; Bhattacharya and Keating, 2012). PM is capable of partitioning to generate a
volatile, cytotoxic compound, CEZ, which occurs within the same pH range as our ovarian
culture system (Colvin et al., 1976; Lu and Chan, 1996; Shulman-Roskes et al., 1998). The
potential ovotoxicity of a volatile metabolite of CPA was suggested in a study due to an
observed “neighboring well effect” (Flowers et al., 2000) in cultured neonatal rat ovaries
(Desmeules and Devine, 2006). Ovotoxicity of this volatile PM metabolite, however,
remains uncharacterized. This present study evaluated the generation of a volatile compound
from PM, which we strongly believe is CEZ and designate as VC, and determined the
ovotoxicity of this compound relative to that of PM using a neonatal rat ovary culture
system.
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To confirm our hypothesis that VC was being generated in the culture system, PND4 control
ovaries were cultured in a separate incubator from those exposed to PM and VC to eliminate
contamination from the volatile compound. Thus, in another incubator, PM exposed ovaries
were in one culture plate and a second culture plate contained ovaries in control media that
were being evaluated for the volatile compound exposure. Histological evaluation
demonstrated that VC depletes primordial follicles, while PM is ovotoxic to primary and
secondary follicles ultimately leading to depletion of all follicle types. This could potentially
be due to increased recruitment from the primordial follicle pool to replace depleted, more
developed follicles, as has been shown previously with CPA (Kalich-Philosoph et al., 2013)
and another ovotoxic compound, 4-vinylcyclohexene diepoxide (Keating et al., 2009). VC
exposure reduced the number of secondary follicles after 2 days of exposure, which could
indicate that either the VC depleted the secondary follicles or that their development was
hindered. The numbers of secondary follicles at this stage were very low (~2 per ovary in
controls) and there was a lot of variability within the PM-treated ovaries, thus whether this
observed VC-induced reduction of secondary follicles is physiologically relevant is unclear.
It is important to note that PM exposed ovaries are exposed simultaneously to VC thus
complicating compound-specific analysis. Nonetheless, this experiment confirmed that a
volatile compound, which literature strongly supports is CEZ, is ovotoxic and liberated from
PM in this culture system.
Our next objective of this study was to determine if ovarian tissue is required for the
biotransformation of PM to VC. This was achieved by culturing an ovary that did not
receive any chemical treatment adjacent to a PM-treated well that lacked an ovary. We
hypothesized that if ovarian tissue is indeed required for the volatile compound formation
that no ovotoxicity would be observed in the untreated ovary. Follicle depletion was
observed in the untreated ovary, further confirming that an ovotoxic and volatile compound,
was liberated spontaneously from the well that contained PM. This experiment clearly
demonstrates that VC generation is independent of ovarian tissue, which agrees with a prior
study that reported that the reaction of PM to CEZ can occur spontaneously (Colvin et al.,
1976; Engle et al.,1979; Watson et al.,1985; Shulman-Roskes et al., 1998), thus providing
additional evidence that CEZ is likely the volatile compound produced. It is also probable
that the ovarian tissue plays a role in detoxification of CEZ, however, this was outside the
scope of the current study, but an avenue that we are pursuing.
Following completion of these experiments, PM, which had been suspended in DMSO and
stored at −20°C, was used for additional histological studies. We noticed observably less
ovotoxicity induced by PM. In order to confirm this suspicion, we determined the impact of
storage on PM-induced ovotoxicity. While this may seem just a routine laboratory analysis,
we thought it important to highlight for future investigators using PM. Follicle enumeration
revealed that the “old” PM was less ovotoxic compared to the “new” PM, therefore,
suggesting that PM degraded while stored at −20°C. Although the short half-life of PM is
known, the apparent degradation of frozen PM was unexpected but noteworthy.
Many studies question the toxicity of PM due to its inability to enter cells because of the
molecules polarity, and although this study does not directly address this question, the
results again suggest that the volatile compound, likely CEZ, could be the primary or sole
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active metabolite of CPA. Separating the effects of VC from PM is challenging since the
ovaries treated with PM are also receiving the highest VC exposure. When VC exposed
ovaries are maintained on a separate plate from PM, VC appears to primarily target the
primordial follicles, however, when VC ovaries were cultured in wells adjacent to PM, all
follicular stages were depleted by VC similarly to those directly treated with PM. In
addition, whether the exposure is acute compared to chronic is worthy of consideration since
a single exposure of PM depleted only secondary follicles, but not other follicular stages,
although the “controls” were likely receiving concurrent exposure to the VC in this
experiment. Thus, proximity to VC (i.e. the concentration of VC), stage of follicular
development, length of exposure and storage conditions are important considerations in
these studies.
Overall, these studies depict both the complexity and ovotoxicity of PM and VC, which
reinforces the need to gain a better understanding of the health impacts and chemical
characteristics of these CPA metabolites. This study’s novel characterization of VC
ovotoxicity is particularly concerning because, if, like rats (Rauen and Norpoth, 1968), it is
being exhaled in the form of CEZ from patients receiving CPA treatment, individuals in
close proximity to the patient would then be at risk of CEZ exposure. Previous studies have
shown that healthcare workers have trace amounts of chemotherapy metabolites in their
urine with one study detecting a high level of airborne CPA in the outpatient clinics
compared to the pre-treatment preparation rooms (Odraska et al., 2011), thus further
supporting that CEZ may be expired from the lungs of patients and exposing individuals in
the vicinity. Whether the level of CEZ expired would be clinically relevant is as yet
unknown, but this study strongly supports that the VC liberated from PM metabolism is an
ovotoxicant worthy of further investigation.
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• PM depletes all stage ovarian follicles in a temporal pattern
• A volatile ovotoxic compound is liberated from PM
• The volatile metabolite depletes primordial follicles
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Figure 1. CPA metabolism
CPA metabolism is initiated by CYP2B and CYP3A to form 4-hydroxycyclophosphamide,
which is non-enzymatically transformed to aldophosphamide. Fragmentation of
aldophosphamide forms PM and further partitioning of PM forms CEZ. Adapted from Hong
and Chan, 2006.
Madden et al. Page 12






















Figure 2. Experimental design to evaluate VC exposure
Control (1% DMSO)-treated PND4 rat ovaries (indicated in yellow) were cultured for 6
days in Incubator A. In a separate incubator, Incubator B, a PM-treated well that lacked an
ovary was plated adjacent to a well containing an ovary floating above control media.
Madden et al. Page 13






















Figure 3. Effect of single PM exposure on growing ovarian follicles
PND4 rat ovaries were cultured for 4 days in control media and exposed to a single 1%
DMSO (vehicle control) or PM (10 μM or 30 μM). Following eight additional days of
culture, follicles were classified and counted: (A) Primordial Follicles; (B) Small Primary
Follicles; (C) Large Primary Follicles; (D) Secondary Follicles. Values (A–D) are mean ±
SE total follicles counted/ovary, n=3; * = different from control in each follicle type, P <
0.05.
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Figure 4. Temporal pattern of PM- and VC-induced ovotoxicity
Cultured PND4 rat ovaries were exposed to (A) control treatment (1% DMSO; CT), (B) PM
(60 μM) or (C) VC on alternate days for 2, 4 or 6 days (Example shown on day 6). Follicles
were classified and counted: (D) Primordial Follicles; (E) Small Primary Follicles; (F) Large
Primary Follicles; (G) Secondary Follicles. Values (D–G) are mean ± SE total follicles
counted/ovary, n=3–4; * = different from control, P < 0.05; † = different from control, P <
0.10; # = different from PM, P < 0.05.
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Figure 5. Ovarian-mediated biotransformation requirement for VC liberation from PM
PND4 rat ovaries were cultured for 6 days in control media adjacent to wells that lacked an
ovary but contained PM (60 μM). Control-treated ovaries (CT) were cultured in a separate
incubator. Follicles were classified and counted: (A) Primordial Follicles; (B) Small Primary
Follicles; (C) Large Primary Follicles; (D) Secondary Follicles. Values (A–D) are mean ±
SE total follicles counted/ovary, n=4; * = different from CT, P < 0.05.
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Figure 6. Impact of storage on PM degradation
Cultured PND4 rat ovaries were exposed on alternate days to stored (“Old”) PM or freshly
resuspended (“New”) PM for 6 days. Follicles were classified and counted: (A) Primordial
Follicles; (B) Small Primary Follicles; (C) Large Primary Follicles; (D) Secondary Follicles.
Values (A–D) are mean ± SE total follicles counted/ovary, n=4; * = different from control in
each follicle type, P < 0.05.
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